Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) have been given a consensus recommendation of “Moderate Buy” by the ten analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $37.7778.

A number of analysts have weighed in on the company. Royal Bank Of Canada cut their price target on Viridian Therapeutics from $45.00 to $41.00 and set an “outperform” rating on the stock in a research note on Thursday, August 7th. Needham & Company LLC cut their price target on Viridian Therapeutics from $36.00 to $34.00 and set a “buy” rating on the stock in a research note on Wednesday, August 6th. The Goldman Sachs Group raised their price target on Viridian Therapeutics from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, August 7th. Jefferies Financial Group assumed coverage on Viridian Therapeutics in a research note on Monday, August 25th. They issued a “buy” rating and a $44.00 price target on the stock. Finally, Wells Fargo & Company cut their price target on Viridian Therapeutics from $27.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 7th.

Institutional Trading of Viridian Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Amalgamated Bank increased its position in shares of Viridian Therapeutics by 49.7% during the first quarter. Amalgamated Bank now owns 2,531 shares of the company’s stock worth $34,000 after purchasing an additional 840 shares in the last quarter. Nuveen Asset Management LLC increased its position in shares of Viridian Therapeutics by 198.2% during the fourth quarter. Nuveen Asset Management LLC now owns 681,012 shares of the company’s stock worth $13,055,000 after purchasing an additional 452,627 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of Viridian Therapeutics by 17.0% during the first quarter. Principal Financial Group Inc. now owns 208,836 shares of the company’s stock worth $2,815,000 after purchasing an additional 30,392 shares in the last quarter. Rhumbline Advisers increased its position in shares of Viridian Therapeutics by 4.6% during the first quarter. Rhumbline Advisers now owns 104,559 shares of the company’s stock worth $1,409,000 after purchasing an additional 4,621 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Viridian Therapeutics by 29.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 115,782 shares of the company’s stock worth $2,220,000 after purchasing an additional 26,286 shares in the last quarter.

Viridian Therapeutics Stock Down 0.3%

Viridian Therapeutics stock opened at $18.38 on Tuesday. Viridian Therapeutics has a 1-year low of $9.90 and a 1-year high of $27.20. The company has a debt-to-equity ratio of 0.04, a current ratio of 11.01 and a quick ratio of 11.01. The stock has a market cap of $1.50 billion, a PE ratio of -4.80 and a beta of 0.53. The stock’s fifty day moving average is $17.01 and its two-hundred day moving average is $15.14.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($1.00) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.00). Viridian Therapeutics had a negative return on equity of 78.95% and a negative net margin of 112,806.88%.The company had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.05 million. During the same period last year, the firm earned ($0.81) earnings per share. Viridian Therapeutics’s quarterly revenue was up 4.2% on a year-over-year basis. On average, sell-side analysts expect that Viridian Therapeutics will post -4.03 EPS for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.